Amit M. Oza

University Health Network — Canada

Medicine · Health Sciences

103h-index56.5kcitations1.2kworks1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(603), PARP inhibition in cancer therapy(369), Cancer Genomics and Diagnostics(158), Endometrial and Cervical Cancer Treatments(115), BRCA gene mutations in cancer(103)

Publications1.2k total

Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis
Cancer·2025Open Access
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2025Open Access
Supplementary Figure S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S7 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
Supplementary Figure S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S6 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Table S1 from Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial
2025Open Access
Supplementary Figure S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Supplementary Figure S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
2025Open Access
Reporting and enrollment disparities in hematologic malignancy trials between 2000–2023
Leukemia & lymphoma/Leukemia and lymphoma·2025
LONG-TERM FOLLOW-UP OF SELINEXOR MAINTENANCE TREATMENT IN PATIENTS WITH TP53 WILD TYPE ADVANCED/RECURRENT ENDOMETRIAL CANCER: INTERMEDIATE ENDPOINTS BY MISMATCH REPAIR STATUS IN THE ENGOT-EN5/GOG-3055/SIENDO STUDY
International Journal of Gynecological Cancer·2025
ADHERENCE TO GUIDELINE-RECOMMENDED TESTING FOR PENICILLIN ALLERGY IN AN ACADEMIC ALLERGY CLINIC
Annals of Allergy Asthma & Immunology·2025
REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
International Journal of Gynecological Cancer·2025
page 1 of 60Next →

Frequent Co-authors

Nicoletta Colombo(12), Michael Friedländer(12), Ana Oaknin(11), Susana Banerjee(11), Diane Provencher(11), Anne Floquet(10), Jonathan A. Ledermann(10), Giovanni Scambia(9), Alexandra Léary(9), Ignace Vergote(9), Anna V. Tinker(8), Éric Pujade-Lauraine(8), Isabelle Ray‐Coquard(8), Clare L. Scott(8), David M. O’Malley(8), Iain A. McNeish(8), Gabe S. Sonke(7), Bradley J. Monk(7), Robert L. Coleman(7), Lara Maloney(7)